BMEA.US Biomea Fusion Inc

Healthcare Biotechnology USA Stocks
0.5822 USD
Close of Nov 14, 2026
0.5401 2.24
Market cap
USD 42.3M
P/E
-
P/B
5.41x
ROE
-473.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BMEA.US undervalued?

Graham number

The Graham number of Biomea Fusion Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biomea Fusion Inc fundamental analysis

No fundamental analysis for Biomea Fusion Inc yet.

Biomea Fusion Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biomea Fusion Inc

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; a…

Full company profile